Who is the CEO of Dr Agarwals Health Care Limited?
- Answer Field
-
The CEO of Dr Agarwal's Health Care Limited is Dr Adil Agarwal.
BAJAJ BROKING
Dr Agarwal's Health Care Limited, established in 2010, is a leading provider of eye care services in India. The company offers an extensive range of treatments, including cataract and refractive surgeries, consultations, diagnostics, non-surgical procedures, and the sale of optical products, contact lenses, and pharmaceutical items. As of September 30, 2024, its expansive network spans 14 states and 4 union territories, with 209 facilities, including 28 hubs and 165 spokes, catering to patients across metro and non-metro cities.
During the six months leading up to September 30, 2024, the company served 1.15 million patients and performed 140,787 surgeries. Known for advanced procedures like robotic cataract surgery, LASIK, SMILE, and corneal transplants, Dr Agarwal's Health Care is well-positioned to capitalise on the growing demand for eye care services in India. With 737 skilled doctors, the IPO presents an opportunity for investors eyeing this thriving healthcare segment.
For more details, visit the Dr. Agarwal’s IPO page.
Details | Information |
IPO Date | January 29, 2025 to January 31, 2025 |
Issue Size | 7,53,04,970 shares (aggregating up to ₹3,027.26 Cr) |
Price Band | ₹382 to ₹402 per share |
Lot Size | 35 shares |
Listing At | BSE, NSE |
Purpose of the IPO
Repayment or prepayment of specific borrowings, either partially or fully.
General corporate purposes.
Potential unidentified inorganic acquisitions.
Event | Date |
IPO Open Date | Wednesday, January 29, 2025 |
IPO Close Date | Friday, January 31, 2025 |
Basis of Allotment | Monday, February 3, 2025 |
Initiation of Refunds | Tuesday, February 4, 2025 |
Credit of Shares to Demat | Tuesday, February 4, 2025 |
Listing Date | Wednesday, February 5, 2025 |
Cut-off time for UPI mandate confirmation | 5 PM on January 31, 2025 |
Price Band for the IPO
₹382 to ₹402 per share.
Minimum Lot Size and Application Details
Application | Lots | Shares | Amount |
Retail (Min) | 1 | 35 | ₹14,070 |
Retail (Max) | 14 | 490 | ₹1,96,980 |
S-HNI (Min) | 15 | 525 | ₹2,11,050 |
S-HNI (Max) | 71 | 2,485 | ₹9,98,970 |
B-HNI (Min) | 72 | 2,520 | ₹10,13,040 |
Online Application Process
Log in to Your Trading Account
Access your trading account through your broker’s platform.
Navigate to the IPO Section
Go to the IPO section to view active IPO listings.
Select Dr. Agarwal’s IPO
Find "Dr. Agarwal’s IPO" and click on the ‘Apply’ button.
Enter Application Details
Specify the number of lots (minimum lot size: 35 shares) and the bid price within the range of ₹382 to ₹402 per share.
Provide Your UPI ID
Enter your UPI ID for payment authorization. Ensure that sufficient funds are available in your linked account.
Review and Submit
Verify all the details entered before submitting the application. Approve the UPI mandate before 5 PM on January 31, 2025, to complete your application process.
Key Financial Metrics
Total Assets: Grew from ₹1,026.13 crore in FY22 to ₹3,393.41 crore as of September 2024.
Revenue: Reached ₹837.94 crore in FY24.
Profit After Tax (PAT): Stood at ₹39.56 crore for September 2024.
Net Worth: Increased from ₹212.34 crore in FY22 to ₹1,502.67 crore as of September 2024.
Reserves and Surplus: Recorded at ₹1,509.11 crore (Sept 2024), growing steadily over the years.
Total Borrowings: Increased to ₹373.68 crore (Sept 2024) from ₹290.18 crore in FY22.
Recent Performance and Growth Prospects
The company has experienced significant growth in its total assets, reflecting its expanding scale of operations.
Revenue generation has consistently increased, showcasing robust business performance.
The company has maintained profitability, underlining its ability to generate sustainable earnings.
Strengthened net worth and reserves highlight financial stability and long-term growth potential.
The steady rise in reserves and surplus indicates strong financial management and reinvestment strategies.
An increase in borrowings suggests strategic investments to support future growth initiatives.
Potential Risks of Investing in the IPO
The company’s increasing borrowings may indicate higher financial obligations, which could impact profitability in the long run.
Reliance on advanced technologies and procedures could pose a challenge if competitors adopt similar innovations, intensifying market competition.
Opportunities and Growth Potential
An expansive and well-established network across metro and non-metro cities positions the company to cater to a growing demand for eye care services in India.
The company’s expertise in advanced surgical procedures, such as robotic cataract surgery and LASIK, presents a competitive edge in the healthcare sector.
KPI | Values |
ROE | 9.33% |
ROCE | 14.61% |
RoNW | 6.21 |
PAT Margin | 6.90 |
Price to Book Value | 7.96 |
Registrar | Lead Manager(s) |
Kfin Technologies Limited | Kotak Mahindra Capital Company Limited, Morgan Stanley India Company Pvt Ltd, Jefferies India Private Limited, Motilal Oswal Investment Advisors Limited |
Dr. Agarwal's Health Care Limited
1 st Floor, Buhari Towers
No.4, Moores Road, Off Greams Road,
Near Asan Memorial School, Chennai 600 006
Phone: +91 44 4378 7777
Email: secretarial@dragarwal.com
Website: https://dragarwals.co.in/
Dr Agarwal's Health Care Limited's IPO highlights its strategic expansion and commitment to advanced eye care services. With a strong network of 209 facilities across 14 states and 4 union territories, the company has demonstrated steady growth in revenue, profitability, and financial stability. Its focus on cutting-edge procedures and increasing patient reach underscores its role in addressing India's growing eye care demand.
The IPO offers investors a glimpse into a thriving healthcare segment, backed by experienced leadership and robust operational metrics. Potential risks include increasing borrowings and competitive challenges. Nonetheless, the company's extensive presence, specialised expertise, and financial growth position it as a noteworthy player in India’s healthcare landscape.
Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Dr. Agarwal’s IPO.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
The CEO of Dr Agarwal's Health Care Limited is Dr Adil Agarwal.
Dr Agarwal's Health Care Limited primarily operates in the eye care sector, offering services such as cataract and refractive surgeries, diagnostics, consultations, and the sale of optical products and pharmaceutical items. Its business model is sustainable in the long term due to its wide service network, advanced surgical procedures, and increasing demand for quality eye care in both metro and non-metro cities.
The issue size of the IPO is 7,53,04,970 shares, aggregating up to ₹3,027.26 crore.
‘Pre-apply’ allows investors to place their IPO applications in advance through their trading platforms, ensuring readiness before the IPO officially opens. The application will be processed when the IPO subscription period begins.
The lot size is 35 shares, and the minimum order quantity for retail investors is 1 lot (35 shares).
The basis of allotment will be finalised on Monday, February 3, 2025.
The registrar for the IPO is Kfin Technologies Limited.
As of now, no governance issues or red flags have been publicly reported in the company’s leadership or board structure.
No Result Found
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading